首頁 > 市場調查報告書 > 製藥

藥物開發開發業務受託機關

市場調查報告書

商品編碼

1469845

全球小分子創新者 API CDMO 市場研究報告 - 2024 年至 2032 年產業分析、規模、佔有率、成長、趨勢與預測

Global Small Molecule Innovator API CDMO Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

出版日期: 2024年04月01日 | 出版商:

Value Market Research | 英文 172 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄圖表

全球小分子創新 API CDMO 市場需求預計將從 2023 年的 301.6 億美元達到 2032 年近 573.9 億美元的市場規模，2024-2032 年研究期間複合年成長率為 7.41%。

研究報告涵蓋波特五力模型、市場吸引力分析和價值鏈分析。這些工具有助於清晰地了解行業結構並評估全球範圍內的競爭吸引力。此外，這些工具也對小分子創新藥物 api cdmo 全球市場的各個細分市場進行了包容性評估。小分子創新者 api cdmo 產業的成長和趨勢為本研究提供了整體方法。

市場區隔

小分子創新者 api cdmo 市場報告的這一部分提供了國家和區域層面細分市場的詳細資料，從而幫助戰略家確定相應產品或服務的目標人群以及即將到來的機會。

按階段類型

臨床前
臨床（一期、二期、三期）
商業的

依客戶類型

製藥（小型、中型、大型）
生物技術（小型、中型、大型）

按治療領域

心血管疾病
腫瘤學
呼吸系統疾病
神經病學
代謝紊亂
傳染性疾病
其他

區域分析

本節涵蓋區域展望，重點介紹北美、歐洲、亞太地區、拉丁美洲以及中東和非洲小分子創新 API CDMO 市場當前和未來的需求。此外，該報告重點關注所有主要地區各個應用領域的需求、估計和預測。

該研究報告還涵蓋了市場主要參與者的全面概況以及對全球競爭格局的深入了解。小分子創新 API CDMO 市場的主要參與者包括 Lonza Group Ltd.、Novo Holdings (Catalent Inc.)、Thermo Fisher Scientific, Inc.、Siegfried Holding AG、Recipharm AB、CordenPharma International、Samsung Biologics、LabCorp、Ajinomoto Bio-醫藥服務、Piramal Pharma Solutions、Jubilant Life Sciences (Jubilant Biosys Ltd.)、藥明康德股份有限公司。概況、合作、新產品開發、新產品發布和其他發展。

如果您有任何客製化要求，請寫信給我們。我們的研究團隊可以根據您的需求提供客製化報告。

區域展望
介紹
北美銷售分析
- 概覽、歷史與預測資料銷售分析
- 北美按細分市場銷售分析
- 北美按國家銷售分析
- 美國銷售分析
- 加拿大銷售分析
- 墨西哥銷售分析
歐洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 歐洲按細分市場銷售分析
- 歐洲按國家銷售分析
- 英國銷售分析
- 法國銷售分析
- 德國銷售分析
- 義大利銷售分析
- 俄羅斯銷售分析
- 歐洲其他地區銷售分析
亞太地區銷售分析
- 概覽、歷史與預測資料銷售分析
- 亞太地區按細分市場銷售分析
- 亞太地區按國家銷售分析
- 中國銷售分析
- 印度銷售分析
- 日本銷售分析
- 韓國銷售分析
- 澳洲銷售分析
- 東南亞銷售分析
- 亞太地區其他地區銷售分析
拉丁美洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 拉丁美洲按細分市場銷售分析
- 拉丁美洲按國家銷售分析
- 巴西銷售分析
- 阿根廷銷售分析
- 秘魯銷售分析
- 智利銷售分析
- 拉丁美洲其他地區銷售分析
中東和非洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 中東和非洲按細分市場銷售分析
- 中東和非洲按國家銷售分析
- 沙烏地阿拉伯銷售分析
- 阿拉伯聯合大公國銷售分析
- 以色列銷售分析
- 南非銷售分析
- 中東其他地區和非洲銷售分析

第 9 章：小分子創新 API CDMO 公司的競爭格局

小分子創新者 API CDMO 市場競爭
夥伴關係/協作/協議
併購
新產品發布
其他發展

第 10 章：公司簡介

頂級公司市佔率分析
市場集中度
Lonza Group Ltd.

公司簡介
公司收入
產品
最近的發展

Novo Holdings (Catalent Inc.)

公司簡介
公司收入
產品
最近的發展

Thermo Fisher Scientific Inc.

公司簡介
公司收入
產品
最近的發展

Siegfried Holding AG

公司簡介
公司收入
產品
最近的發展

Recipharm AB

公司簡介
公司收入
產品
最近的發展

CordenPharma International

公司簡介
公司收入
產品
最近的發展

Samsung Biologics

公司簡介
公司收入
產品
最近的發展

LabCorp

公司簡介
公司收入
產品
最近的發展

Ajinomoto Bio-Pharma Services

公司簡介
公司收入
產品
最近的發展

Piramal Pharma Solutions

公司簡介
公司收入
產品
最近的發展

Jubilant Life Sciences (Jubilant Biosys Ltd.)

公司簡介
公司收入
產品
最近的發展

WuXi AppTec Co. Ltd.

公司簡介
公司收入
產品
最近的發展

註 - 在公司概況中，財務詳細資訊和最新發展視情況而定，或對私人公司而言可能不包括在內

簡介目錄圖表

Product Code: VMR112114302

The global demand for Small Molecule Innovator API CDMO Market is presumed to reach the market size of nearly USD 57.39 Billion by 2032 from USD 30.16 Billion in 2023 with a CAGR of 7.41% under the study period 2024 - 2032.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of small molecule innovator api cdmo. The growth and trends of small molecule innovator api cdmo industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the small molecule innovator api cdmo market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Stage Type

Preclinical
Clinical (Phase I, Phase II, Phase III)
Commercial

By Customer Type

Pharmaceutical (Small, Medium, Large)
Biotechnology (Small, Medium, Large)

By Therapeutic Area

Cardiovascular Diseases
Oncology
Respiratory Disorders
Neurology
Metabolic Disorders
Infectious Diseases
Others

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Small Molecule Innovator API CDMO market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Small Molecule Innovator API CDMO market include Lonza Group Ltd., Novo Holdings (Catalent Inc.), Thermo Fisher Scientific, Inc., Siegfried Holding AG, Recipharm AB, CordenPharma International, Samsung Biologics, LabCorp, Ajinomoto Bio-Pharma Services, Piramal Pharma Solutions, Jubilant Life Sciences (Jubilant Biosys Ltd.), WuXi AppTec Co., Ltd. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

1. PREFACE

1.1. Report Description
- 1.1.1 Objective
- 1.1.2 Target Audience
- 1.1.3 Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1 Market Research Process
- 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3. SMALL MOLECULE INNOVATOR API CDMO - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Stage Type
- 3.7.2 Market Attractiveness Analysis By Customer Type
- 3.7.3 Market Attractiveness Analysis By Therapeutic Area
- 3.7.4 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1 List of Raw Materials
- 4.2.2 Raw Material Manufactures List
- 4.2.3 Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1 Direct Marketing
- 4.4.2 Indirect Marketing
- 4.4.3 Marketing Channel Development Trend

5. GLOBAL SMALL MOLECULE INNOVATOR API CDMO MARKET ANALYSIS BY STAGE TYPE

5.1. Overview By Stage Type
5.2. Historical and Forecast Data
5.3. Analysis By Stage Type
5.4. Preclinical Historic and Forecast Sales By Regions
5.5. Clinical (Phase I, Phase II, Phase III) Historic and Forecast Sales By Regions
5.6. Commercial Historic and Forecast Sales By Regions

6. GLOBAL SMALL MOLECULE INNOVATOR API CDMO MARKET ANALYSIS BY CUSTOMER TYPE

6.1. Overview By Customer Type
6.2. Historical and Forecast Data
6.3. Analysis By Customer Type
6.4. Pharmaceutical (Small, Medium, Large) Historic and Forecast Sales By Regions
6.5. Biotechnology (Small, Medium, Large) Historic and Forecast Sales By Regions

7. GLOBAL SMALL MOLECULE INNOVATOR API CDMO MARKET ANALYSIS BY THERAPEUTIC AREA

7.1. Overview By Therapeutic Area
7.2. Historical and Forecast Data
7.3. Analysis By Therapeutic Area
7.4. Cardiovascular Diseases Historic and Forecast Sales By Regions
7.5. Oncology Historic and Forecast Sales By Regions
7.6. Respiratory Disorders Historic and Forecast Sales By Regions
7.7. Neurology Historic and Forecast Sales By Regions
7.8. Metabolic Disorders Historic and Forecast Sales By Regions
7.9. Infectious Diseases Historic and Forecast Sales By Regions
7.10. Others Historic and Forecast Sales By Regions

8. GLOBAL SMALL MOLECULE INNOVATOR API CDMO MARKET ANALYSIS BY GEOGRAPHY

8.1. Regional Outlook
8.2. Introduction
8.3. North America Sales Analysis
- 8.3.1 Overview, Historic and Forecast Data Sales Analysis
- 8.3.2 North America By Segment Sales Analysis
- 8.3.3 North America By Country Sales Analysis
- 8.3.4 United States Sales Analysis
- 8.3.5 Canada Sales Analysis
- 8.3.6 Mexico Sales Analysis
8.4. Europe Sales Analysis
- 8.4.1 Overview, Historic and Forecast Data Sales Analysis
- 8.4.2 Europe By Segment Sales Analysis
- 8.4.3 Europe By Country Sales Analysis
- 8.4.4 United Kingdom Sales Analysis
- 8.4.5 France Sales Analysis
- 8.4.6 Germany Sales Analysis
- 8.4.7 Italy Sales Analysis
- 8.4.8 Russia Sales Analysis
- 8.4.9 Rest Of Europe Sales Analysis
8.5. Asia Pacific Sales Analysis
- 8.5.1 Overview, Historic and Forecast Data Sales Analysis
- 8.5.2 Asia Pacific By Segment Sales Analysis
- 8.5.3 Asia Pacific By Country Sales Analysis
- 8.5.4 China Sales Analysis
- 8.5.5 India Sales Analysis
- 8.5.6 Japan Sales Analysis
- 8.5.7 South Korea Sales Analysis
- 8.5.8 Australia Sales Analysis
- 8.5.9 South East Asia Sales Analysis
- 8.5.10 Rest Of Asia Pacific Sales Analysis
8.6. Latin America Sales Analysis
- 8.6.1 Overview, Historic and Forecast Data Sales Analysis
- 8.6.2 Latin America By Segment Sales Analysis
- 8.6.3 Latin America By Country Sales Analysis
- 8.6.4 Brazil Sales Analysis
- 8.6.5 Argentina Sales Analysis
- 8.6.6 Peru Sales Analysis
- 8.6.7 Chile Sales Analysis
- 8.6.8 Rest of Latin America Sales Analysis
8.7. Middle East & Africa Sales Analysis
- 8.7.1 Overview, Historic and Forecast Data Sales Analysis
- 8.7.2 Middle East & Africa By Segment Sales Analysis
- 8.7.3 Middle East & Africa By Country Sales Analysis
- 8.7.4 Saudi Arabia Sales Analysis
- 8.7.5 UAE Sales Analysis
- 8.7.6 Israel Sales Analysis
- 8.7.7 South Africa Sales Analysis
- 8.7.8 Rest Of Middle East And Africa Sales Analysis

9. COMPETITIVE LANDSCAPE OF THE SMALL MOLECULE INNOVATOR API CDMO COMPANIES

9.1. Small Molecule Innovator API CDMO Market Competition
9.2. Partnership/Collaboration/Agreement
9.3. Merger And Acquisitions
9.4. New Product Launch
9.5. Other Developments

10. COMPANY PROFILES OF SMALL MOLECULE INNOVATOR API CDMO INDUSTRY

10.1. Top Companies Market Share Analysis
10.2. Market Concentration Rate
10.3. Lonza Group Ltd.
- 10.3.1 Company Overview
- 10.3.2 Company Revenue
- 10.3.3 Products
- 10.3.4 Recent Developments
10.4. Novo Holdings (Catalent Inc.)
- 10.4.1 Company Overview
- 10.4.2 Company Revenue
- 10.4.3 Products
- 10.4.4 Recent Developments
10.5. Thermo Fisher Scientific Inc.
- 10.5.1 Company Overview
- 10.5.2 Company Revenue
- 10.5.3 Products
- 10.5.4 Recent Developments
10.6. Siegfried Holding AG
- 10.6.1 Company Overview
- 10.6.2 Company Revenue
- 10.6.3 Products
- 10.6.4 Recent Developments
10.7. Recipharm AB
- 10.7.1 Company Overview
- 10.7.2 Company Revenue
- 10.7.3 Products
- 10.7.4 Recent Developments
10.8. CordenPharma International
- 10.8.1 Company Overview
- 10.8.2 Company Revenue
- 10.8.3 Products
- 10.8.4 Recent Developments
10.9. Samsung Biologics
- 10.9.1 Company Overview
- 10.9.2 Company Revenue
- 10.9.3 Products
- 10.9.4 Recent Developments
10.10. LabCorp
- 10.10.1 Company Overview
- 10.10.2 Company Revenue
- 10.10.3 Products
- 10.10.4 Recent Developments
10.11. Ajinomoto Bio-Pharma Services
- 10.11.1 Company Overview
- 10.11.2 Company Revenue
- 10.11.3 Products
- 10.11.4 Recent Developments
10.12. Piramal Pharma Solutions
- 10.12.1 Company Overview
- 10.12.2 Company Revenue
- 10.12.3 Products
- 10.12.4 Recent Developments
10.13. Jubilant Life Sciences (Jubilant Biosys Ltd.)
- 10.13.1 Company Overview
- 10.13.2 Company Revenue
- 10.13.3 Products
- 10.13.4 Recent Developments
10.14. WuXi AppTec Co. Ltd.
- 10.14.1 Company Overview
- 10.14.2 Company Revenue
- 10.14.3 Products
- 10.14.4 Recent Developments